Heart failure and treatment with Sodium-glucose Co-transporter Inhibitor (SGLT2): dapagliflozin and its effects on the cardiac system
DOI:
https://doi.org/10.34119/bjhrv7n2-302Keywords:
heart, SGLT2, dapagliflozin, insufficiency, treatmentAbstract
This article thoroughly examines the effectiveness of treatment with dapagliflozin, a sodium-glucose co-transporter inhibitor, in the context of heart failure. The primary focus of this analysis lies in evaluating patients' clinical condition, the diagnostic procedures employed, and the various medications used as part of the treatment regimen. The objective of this investigation is based on a meticulous analysis of relevant scientific articles. Classified as documentary research within the field of Applied Linguistics, this study draws upon research covering classification, pathophysiology, clinical presentation, diagnosis, pharmacological treatment, and the role of SGLT2 inhibitors in heart failure as its primary theoretical framework. The findings indicate dapagliflozin's efficacy in reducing the heart's ejection fraction, regardless of the presence of diabetes. However, it emphasizes the importance of a comprehensive medical assessment before initiating the use of this medication, highlighting the need for caution and appropriate professional supervision.
References
ALI, A. E. et al. Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Global Heart, v. 18, n. 1, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/37636033/>. Acesso em: 12 fev. 2024.
ARNAUD JÚNIOR, F. de S. et al. Avanços na abordagem terapêutica da insuficiência cardíaca com fração de ejeção preservada (ICFEP): O uso de inibidores de SGLT-2. Brazilian Journal of Health Review, v. 6, n. 1, 2023. Disponível em: <https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/55983>. Acesso em: 12 fev. 2024.
BARRETTO, A. C. P., & RAMIRES, J. A. F. Insuficiência Cardíaca. Arquivos Brasileiros de Cardiologia, v. 71, n. 4, 1998. Disponível em: https://www.scielo.br/j/abc/a/VCQkdfNs5QNyTYhp8WdnMdN/?format=pdf&lang=pt. Acesso em: 12 fev. 2024.
BORLAUG, B. A. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, v. 11, n. 9, 2014. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24958077/. Acesso em: 12 fev. 2024.
BORLAUG, B. A. Tratamento e prognóstico da insuficiência cardíaca com fração de ejeção de médio alcance. UpToDate. Jun, 2020. Disponível em: <https://www.uptodate.com/contents/treatment-and-prognosis-of-heart-failure-with-mid-range-ejection-fraction?search=INSUFICIÊNCIA%20CARDIACA&source=search_result&selectedTitle=22~150&usage_type=default&display_rank=21#H2277438081>. Acesso em: 12 fev. 2024.
BORLAUG, B. A. et al. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial. Circulation, v. 148, n. 10, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/37534453/>. Acesso em: 12 fev. 2024.
BUTT, J. H. et al. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC Heart Fail, v. 11, n. 4, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/36881399/>. Acesso em: 12 fev. 2024.
COLUCCI, W. S. Visão geral do manejo da insuficiência cardíaca com fração de ejeção reduzida em adultos. UpToDate. Mai, 2022. Disponível em: <https://www.uptodate.com/contents/overview-of-the-management-of-heart-failure-with-reduced-ejection-fraction-in-adults?search=INSUFICIÊNCIA%20CARDIACA&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2>. Acesso em: 12 fev. 2024.
FREITAS, A. K. E., & CIRINO, R. H. D. Manejo Ambulatorial da Insuficiência Cardíaca Crônica. Revista de Medicina da UFPR, v. 4, n. 3, 2017. Disponível em: https://revistas.ufpr.br/revmedicaufpr/article/view/56397. Acesso em: 12 fev. 2024.
INA, I. L. Reabilitação cardíaca em pacientes com insuficiência cardíaca. UpToDate. Jun, 2021. Disponível em:https://www.uptodate.com/contents/cardiac-rehabilitation-in-patients-with-heart-failure?sectionName=For%20heart%20failure%20with%20preserved%20or%20mid-range%20ejection%20fraction&search=INSUFICIÊNCIA%20CARDIACA&topicRef=3461&anchor=H113444405&source=see_link#H113444405>. Acesso em: 12 fev
KIRALI, K., ALTAY, H., & PEHLIVANOGLU, S. Heart Failure with Preserved Ejection Fraction. In K. Kirali (Ed.), Cardiomyopathies - Types and Treatments, IntechOpen, 2017. Disponível em: https://www.intechopen.com/books/5425. Acesso em: 12 fev. 2024.
KONDO, T. et al. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. J Am Coll Cardiol, v. 82, n. 10, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/37610398/>. Acesso em: 12 fev. 2024.
KONDO, T. et al. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circ Heart Fail, v. 16, n. 12, 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37886880/. Acesso em: 12 fev. 2024.
MANN, D. L. Mechanisms and models in heart failure: A combinatorial approach. Circulation, v. 31, n. 100(9), 1999. Disponível em: https://pubmed.ncbi.nlm.nih.gov/10468532/. Acesso em: 12 fev. 2024.
MANN, D. L. et al. Braunwald’s heart disease: a textbook of cardiovascular medicine (10th ed.). Philadelphia: Elsevier, 2015. Acesso em: 12 fev. 2024.
MARTUCHELI, M. de O. et al. Medicamentos na insuficiência cardíaca: revisão bibliográfica: Medications in heart failure: a literature review. Brazilian Journal of Development, v. 8, n. 9, 2022. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/52230. Acesso em: 12 fev. 2024.
MOREIRA, M. C. V. Insuficiência cardíaca na era moderna: das melhores evidências para a prática clínica. Revista de Medicina de Minas Gerais, v. 17, 2007. Disponível em: https://www.rmmg.org/artigo/detalhes/237#. Acesso em: 12 fev. 2024.
NASSIF, M. E. et al. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. Circ Heart Fail, v. 16, n. 7, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/37203441/>. Acesso em: 12 fev. 2024.
NGUYEN, B. N. et al. Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. Int J Cardiol, v. 376, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/36736672/>. Acesso em: 12 fev. 2024.
OLUCCI, W. S., & BORLAUG, B. A. Tratamento e prognóstico da insuficiência cardíaca com fração de ejeção preservada. UpToDate. Fev, 2022. Disponível em: <https://www.uptodate.com/contents/treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction?search=INSUFICIÊNCIA%20CARDIACA&source=search_result&selectedTitle=44~150&usage_type=default&display_rank=43#H3248283728>. Acesso em: 12 fev. 2024.
PAFFER, P. T. et al. Inibidores SGLT-2 no tratamento da insuficiência cardíaca com fração de ejeção reduzida. Anais da Faculdade de Medicina de Olinda, v. 1, n. 8, 2022. Disponível em: <https://afmo.emnuvens.com.br/afmo/article/view/229>. Acesso em: 12 fev. 2024.
PASCUAL-FIGAL, D. A. et al. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study. European Journal of Heart Failure, v. 25, n. 8, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/37211950/>. Acesso em: 12 fev. 2024.
PEIKERT, A. et al. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. JACC Heart Fail, v. 11, n. 10, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/37294244/>. Acesso em: 12 fev. 2024.
PONIKOWSKI, P. et al. 2016 ESC Guideline for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, v. 37, 2016. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27206819/. Acesso em: 12 fev. 2024.
REDFIELD, M. M., & BORLAUG, B. A. Heart Failure With Preserved Ejection Fraction: A Review. JAMA, v. 329, n. 10, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/36917048/>. Acesso em: 12 fev. 2024.
ROHDE, L. E. P. et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arquivos Brasileiros de Cardiologia, v. 111, n. 3, 2018. Disponível em: https://abccardiol.org/article/diretriz-brasileira-de-insuficiencia-cardiaca-cronica-eaguda/. Acesso em: 12 fev. 2024.
SOCIEDADE BRASILEIRA DE CARDIOLOGIA. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arquivos Brasileiros de Cardiologia, v. 111, n. 3, 2018. Acesso em: 12 fev. 2024.
SOCIEDADE BRASILEIRA DE CARDIOLOGIA. III Diretriz brasileira de insuficiência cardíaca Crônica. Arquivos Brasileiros de Cardiologia, 2009. Disponível em: <https://www.scielo.br/j/abc/a/XrJZJkL945HZqpd3dZgdPrf/?lang=pt&format=pdf>. Acesso em: 12 fev. 2024.
YANCY, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, v. 128, n. 16, 2013. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23747642/. Acesso em: 12 fev. 2024.
ZAKERI, R., & COWIE, M. R. Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart, v. 104, n. 5, 2018. Disponível em: https://pubmed.ncbi.nlm.nih.gov/29305560/. Acesso em: 12 fev. 2024.
